SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

Myriad Genetics Completes EndoPredict Sale to Eurobio Scientific and Advances International Reorganization

NextEdge Admin

02 Aug 2024

2 min 34 sec

Myriad Genetics, Inc. , a leader in genetic testing and precision medicine, announced the sale of its EndoPredict® business to Eurobio Scientific, a prominent French group in in vitro medical diagnostics and life sciences. This transaction includes a license for Eurobio to sell Prolaris® in vitro diagnostic kits outside the U.S.

In May 2024, Myriad reorganized its International operations to align resources with domestic opportunities while maintaining service for global biopharma partners and patients. The sale of EndoPredict builds on Myriad's efforts to drive profitable growth across its portfolio. Myriad retains the rights to produce and sell EndoPredict in the U.S. as part of Precise™ Oncology Solutions, which includes precision medicine tools for various cancers such as breast, prostate, ovarian, pancreatic, endometrial, and colon cancer.

Paul J. Diaz, President and CEO of Myriad Genetics, stated, “The reorganization of Myriad’s International operations will enable us to continue growing our oncology and biopharma business in Europe and Asia, including Japan, through a more efficient commercial distribution model that reduces organizational complexity and enterprise risk.”

EndoPredict is a prognostic test for breast cancer that predicts the risk of recurrence, helping to identify patients who may safely forgo chemotherapy. Prolaris is a molecular diagnostic test providing personalized information about the aggressiveness of prostate cancer.

Myriad Genetics is dedicated to advancing health and well-being through genetic testing and precision medicine. The company develops genetic tests that assess the risk of disease development or progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.